填塞还是栓塞:美国创伤外科协会多中心评估骨盆骨折出血控制干预
这项前瞻性多中心观察研究纳入2022至2024年钝性创伤相关骨盆环骨折、收缩压<90 mmHg且24小时内输注≥4 U浓缩红细胞和/或接受出血控制干预的患者。948例中524例接受PPP(n=68)、PAE(n=390)或两者(n=66)。PPP组损伤严重度评分更高(41 vs 34)、生理状态更差(最低收缩压62 vs 74 mmHg;乳酸6.4 vs 4.3)且更多接受剖腹术(67.6% vs 23.6%)。PPP组院内死亡率(47.1% vs 18.5%)、24小时死亡率(38.2% vs 4.1%)及3小时内早期死亡(27.9% vs 0.5%)均高于PAE组。校正后PPP与3小时死亡(OR 64.0,95%CI 8.8-465.1)和6小时死亡(OR 15.1,95%CI 4.4-51.7)更高几率相关;逆概率治疗加权分析显示PPP较PAE 6小时死亡概率高19.4%(P<0.001)。作者认为PPP用于更严重出血性休克患者可能解释观察到的更高死亡率。
要点
- 研究纳入钝性骨盆环骨折伴收缩压<90 mmHg且24小时内输注≥4 U浓缩红细胞和/或接受出血控制干预的患者,PPP组损伤更重、生理更差。
- PPP组院内死亡率47.1% vs PAE组18.5%,24小时死亡率38.2% vs 4.1%,3小时内死亡27.9% vs 0.5%(均P<0.001)。
- 校正后PPP较PAE 3小时死亡OR 64.0(95%CI 8.8-465.1)、6小时死亡OR 15.1(95%CI 4.4-51.7)。
- 逆概率治疗加权分析显示PPP较PAE 6小时死亡概率高19.4%(P<0.001)。
- 作者认为PAE是大多数出血性骨盆骨折患者在能快速获得血管内治疗的创伤中心的合适一线治疗。
适用人群与场景
- 钝性创伤相关骨盆环骨折、收缩压<90 mmHg且24小时内输注≥4 U浓缩红细胞和/或接受出血控制干预的患者(2022-2024年)。
研究设计与关键结果
- 前瞻性、多中心、观察性研究,948例中524例接受PPP(n=68,13.0%)、PAE(n=390,74.4%)或两者(n=66,12.6%)。
- PPP组较PAE组损伤严重度评分更高(41 vs 34,p<0.001)、最低收缩压更低(62 vs 74 mmHg)、乳酸更高(6.4 vs 4.3,p<0.001)、更多接受剖腹术(67.6% vs 23.6%,p<0.001)。
- PPP组较PAE组院内死亡率更高(47.1% vs 18.5%,p<0.001)、24小时死亡率更高(38.2% vs 4.1%,p<0.001)、3小时内死亡更多(27.9% vs 0.5%,p<0.001)。
- PPP较PAE 3小时死亡OR 64.0(95%CI 8.8-465.1)、6小时死亡OR 15.1(95%CI 4.4-51.7)。
- 逆概率治疗加权分析显示PPP较PAE 6小时死亡概率高19.4%(p<0.001)。
证据类型、等级与局限
- 证据类型:前瞻性、多中心、观察性研究;证据等级:治疗/护理管理,Level III。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,在能快速获得血管内治疗的创伤中心,PAE是大多数出血性骨盆骨折患者的合适一线治疗。
- 作者认为,PPP用于更严重出血性休克患者可能解释观察到的更高死亡率。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
INTRODUCTION: Mortality from pelvic ring fractures (PRFs) complicated by hemorrhagic shock remains high, and there are limited high-quality data to guide care. We compared two primary hemorrhage control interventions: pelvic angiography +/- embolization (PAE) and preperitoneal pelvic packing (PPP), hypothesizing similar odds of death.
METHODS: A prospective, multicenter, observational study was conducted for individuals with blunt trauma-associated PRF with a systolic blood pressure of <90 mm Hg who received ≥4 U of packed red blood cells within 24 hours and/or used a hemorrhage control intervention (2022-2024). Bivariate comparisons, multivariable regression controlling for several clinical factors, and inverse probability treatment weighting analysis were performed. Primary outcomes were 3- and 6-hour mortality.
RESULTS: Of 948 patients, 524 underwent either PPP (n = 68, 13.0%), PAE (n = 390, 74.4%), or both (n = 66, 12.6%) and comprise the study cohort. Compared with PAE, PPP patients had higher Injury Severity Scores (41 vs. 34, p < 0.001) and worse physiology (lowest systolic blood pressure, 62 vs. 74 mm Hg; lactate, 6.4 vs. 4.3; p < 0.001) and more frequently underwent laparotomy (67.6% vs. 23.6%, p < 0.001). In-hospital (47.1% vs. 18.5%, p < 0.001) and 24-hour (38.2% vs. 4.1%, p < 0.001) mortality were higher in PPP versus PAE with more earlier deaths (27.9% vs. 0.5% within 3 hours, p < 0.001). Preperitoneal pelvic packing was associated with higher odds of death at 3 hours (odds ratio, 64.0; confidence interval, 8.8-465.1) and 6 hours (odds ratio, 15.1; confidence interval, 4.4-51.7) compared with PAE. Inverse probability treatment weighting analysis demonstrated 19.4% higher probability of death at 6 hours for PPP versus PAE ( p < 0.001).
CONCLUSION: Whereas hypotensive patients with PRFs are more likely to undergo PAE, PPP is reserved for patients with more severe hemorrhagic shock, which may account for the observed higher mortality. Findings from this study suggest that PAE is an appropriate first-line therapy for most patients with bleeding pelvic fractures at trauma centers with rapid access to endovascular therapy.
LEVEL OF EVIDENCE: Therapeutic/Care Management; Level III.
参考来源
- Harfouche MN, Sult L, Sciarretta JD, et al. To pack or plug: American Association for the Surgery of Trauma multicenter evaluation of hemorrhage control interventions in pelvic fracture management. J Trauma Acute Care Surg. 2026. PMID: 41533046. doi:10.1097/TA.0000000000004856
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。